Early ALS drug trial halted after safety check
NCT ID NCT03757351
Summary
This early-stage study aimed to check the safety and side effects of an oral drug called DNL747 in people with ALS (Lou Gehrig's disease). It involved 15 participants who took the drug or a placebo in a crossover design. The main goal was to see how the body processes the drug and to monitor for any health problems it might cause.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bioclinica
Orlando, Florida, 32806, United States
-
CHDR
Leiden, South Holland, 2333, Netherlands
-
PRA Health Sciences
Salt Lake City, Utah, 84124, United States
Conditions
Explore the condition pages connected to this study.